The effects of ACTN3 R577X on muscle wasting and repair, and response to therapy [ 2017 - ]

Research Grant

Researchers: Prof Kathryn North (Principal investigator) ,  A/Pr Paul Gregorevic ,  Dr Jane Seto

Brief description Complete loss of ACTN3 is normal and occurs in 1 in 5 people world-wide. While it does not cause disease, loss of ACTN3 results in ~10% reduction in muscle mass and strength. This has tremendous impact not only on the success of elite athletes but also the quality of life in people who are already frail. Precisely how ACTN3 affects muscle mass is unclear. Understanding this will help identify the patients who are at greater risk of muscle wasting and also the therapies that will best treat them.

Funding Amount $1,066,054.00

Funding Scheme Project Grants

Notes Standard Project Grant